Literature DB >> 17434557

Ebola virus-like particle-induced activation of NF-kappaB and Erk signaling in human dendritic cells requires the glycoprotein mucin domain.

Osvaldo Martinez1, Charalampos Valmas, Christopher F Basler.   

Abstract

Dendritic cells (DCs), important early targets of Ebola virus (EBOV) infection in vivo, are activated by Ebola virus-like particles (VLPs). To better understand this phenomenon, we have systematically assessed the response of DCs to VLPs of different compositions. VLPs containing the viral matrix protein (VP40) and the viral glycoprotein (GP), were found to induce a proinflammatory response highly similar to a prototypical DC activator, LPS. This response included the production of several proinflammatory cytokines, activation of numerous transcription factors including NF-kappaB, the functional importance of which was demonstrated by employing inhibitors of NF-kappaB activation, and activation of ERK1/2 MAP kinase. In contrast, VLPs constituted with a mutant GP lacking the heavily glycosylated mucin domain showed impaired NF-kappaB and Erk activation and induced less DC cytokine production. We conclude that the GP mucin domain is required for VLPs to stimulate human dendritic cells through NF-kappaB and MAPK signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17434557      PMCID: PMC2034500          DOI: 10.1016/j.virol.2007.03.020

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  55 in total

1.  Ebola virus can be effectively neutralized by antibody produced in natural human infection.

Authors:  T Maruyama; L L Rodriguez; P B Jahrling; A Sanchez; A S Khan; S T Nichol; C J Peters; P W Parren; D R Burton
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

Review 2.  Introduction: STATs as essential intracellular mediators of cytokine responses.

Authors:  T Decker
Journal:  Cell Mol Life Sci       Date:  1999-09       Impact factor: 9.261

3.  A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus.

Authors:  Amy L Hartman; Jonathan S Towner; Stuart T Nichol
Journal:  Virology       Date:  2004-10-25       Impact factor: 3.616

4.  Differentiation of filoviruses by electron microscopy.

Authors:  T W Geisbert; P B Jahrling
Journal:  Virus Res       Date:  1995-12       Impact factor: 3.303

5.  Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway.

Authors:  Nancy J Sullivan; Mary Peterson; Zhi-yong Yang; Wing-pui Kong; Heinricus Duckers; Elizabeth Nabel; Gary J Nabel
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

6.  Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients.

Authors:  S Baize; E M Leroy; M C Georges-Courbot; M Capron; J Lansoud-Soukate; P Debré; S P Fisher-Hoch; J B McCormick; A J Georges
Journal:  Nat Med       Date:  1999-04       Impact factor: 53.440

7.  Comprehensive analysis of ebola virus GP1 in viral entry.

Authors:  Balaji Manicassamy; Jizhen Wang; Haiqing Jiang; Lijun Rong
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

8.  Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages.

Authors:  Victoria Wahl-Jensen; Sabine K Kurz; Paul R Hazelton; Hans-Joachim Schnittler; Ute Ströher; Dennis R Burton; Heinz Feldmann
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

9.  Ebola virus-like particles protect from lethal Ebola virus infection.

Authors:  Kelly L Warfield; Catharine M Bosio; Brent C Welcher; Emily M Deal; Mansour Mohamadzadeh; Alan Schmaljohn; M Javad Aman; Sina Bavari
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-12       Impact factor: 11.205

Review 10.  Regulation in S phase by E2F.

Authors:  Arthur B Pardee; Chiang J Li; G Prem Veer Reddy
Journal:  Cell Cycle       Date:  2004-09-04       Impact factor: 4.534

View more
  40 in total

1.  Basic residues within the ebolavirus VP35 protein are required for its viral polymerase cofactor function.

Authors:  Kathleen C Prins; Jennifer M Binning; Reed S Shabman; Daisy W Leung; Gaya K Amarasinghe; Christopher F Basler
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

2.  A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry.

Authors:  Anthony C Wong; Rohini G Sandesara; Nirupama Mulherkar; Sean P Whelan; Kartik Chandran
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

Review 3.  Characterization of a putative filovirus vaccine: virus-like particles.

Authors:  Karen A O Martins; Travis K Warren; Sina Bavari
Journal:  Virol Sin       Date:  2013-02-06       Impact factor: 4.327

4.  Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles.

Authors:  Osvaldo Martinez; Lee Tantral; Nirupama Mulherkar; Kartik Chandran; Christopher F Basler
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

5.  Ebola Virus Glycoprotein Promotes Enhanced Viral Egress by Preventing Ebola VP40 From Associating With the Host Restriction Factor BST2/Tetherin.

Authors:  Jean K Gustin; Ying Bai; Ashlee V Moses; Janet L Douglas
Journal:  J Infect Dis       Date:  2015-03-27       Impact factor: 5.226

6.  Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells.

Authors:  Joshua C Johnson; Osvaldo Martinez; Anna N Honko; Lisa E Hensley; Gene G Olinger; Christopher F Basler
Journal:  Antiviral Res       Date:  2014-05-09       Impact factor: 5.970

7.  Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition.

Authors:  Osvaldo Martinez; Joshua Johnson; Balaji Manicassamy; Lijun Rong; Gene G Olinger; Lisa E Hensley; Christopher F Basler
Journal:  Cell Microbiol       Date:  2009-09-22       Impact factor: 3.715

8.  Proteomic analysis of Pichindé virus infection identifies differential expression of prothymosin-alpha.

Authors:  Gavin C Bowick; Kizhake V Soman; He Wang; Judith F Aronson; Bruce A Luxon; Lee O Lomas; David G Gorenstein; Norbert K Herzog
Journal:  J Biomed Biotechnol       Date:  2010-04-18

9.  Ross River virus envelope glycans contribute to type I interferon production in myeloid dendritic cells.

Authors:  Reed S Shabman; Kristin M Rogers; Mark T Heise
Journal:  J Virol       Date:  2008-10-15       Impact factor: 5.103

10.  Differential regulation of type I interferon and epidermal growth factor pathways by a human Respirovirus virulence factor.

Authors:  Grégory Caignard; Anastassia V Komarova; Mehdi Bouraï; Thomas Mourez; Yves Jacob; Louis M Jones; Flore Rozenberg; Astrid Vabret; François Freymuth; Frédéric Tangy; Pierre-Olivier Vidalain
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.